Previous Close | 5.62 |
Open | 5.87 |
Bid | 5.65 x 1500 |
Ask | 5.68 x 800 |
Day's Range | 5.64 - 5.97 |
52 Week Range | 5.11 - 11.91 |
Volume | |
Avg. Volume | 1,960,031 |
Market Cap | 466.271M |
Beta (5Y Monthly) | 2.02 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.02 |
Earnings Date | May 06, 2024 - May 07, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.64 |
Key Insights Significantly high institutional ownership implies Editas Medicine's stock price is sensitive to their...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins.Particip
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer